Shares of Prime Medicine, Inc. (PRME) are surging 7.08% in Wednesday's intraday trading session, following a positive analyst report from Guggenheim. The biotechnology company's stock price jump comes on the heels of Guggenheim analyst Debjit Chattopadhyay reiterating a Buy rating on Prime Medicine, with a price target of $5.00.

The analyst's bullish stance on Prime Medicine appears to have boosted investor confidence, driving the stock's significant upward movement. Guggenheim's maintained Buy rating suggests continued optimism about the company's future prospects and potential for growth in the biotech sector.

While specific details of the analyst's report were not immediately available, the market's strong positive reaction indicates that investors are aligning with Guggenheim's optimistic outlook on Prime Medicine. As always, investors are advised to conduct their own research and consider their individual risk tolerance before making investment decisions based on analyst ratings or market movements.